Refine
Has Fulltext
- yes (21)
Is part of the Bibliography
- yes (21) (remove)
Document Type
- Journal article (20)
- Preprint (1)
Language
- English (21)
Keywords
- PRRT (5)
- positron emission tomography (5)
- CXCR4 (4)
- PET/CT (4)
- multiple myeloma (4)
- PET (3)
- medicine (3)
- molecular imaging (3)
- neuroendocrine tumor (3)
- theranostics (3)
Institute
- Klinik und Poliklinik für Nuklearmedizin (20)
- Medizinische Klinik und Poliklinik II (7)
- Pathologisches Institut (4)
- Institut für Klinische Biochemie und Pathobiochemie (2)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (2)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (1)
- Institut für Klinische Epidemiologie und Biometrie (1)
- Institut für Medizinische Strahlenkunde und Zellforschung (1)
- Institut für diagnostische und interventionelle Neuroradiologie (ehem. Abteilung für Neuroradiologie) (1)
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (1)
- Medizinische Klinik und Poliklinik I (1)
- Neurochirurgische Klinik und Poliklinik (1)
- Neurologische Klinik und Poliklinik (1)
- Urologische Klinik und Poliklinik (1)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 701983 (2)
\(^{11}\)C-methionine-PET in multiple myeloma: a combined study from two different institutions
(2017)
\(^{11}\)C-methionine (MET) has recently emerged as an accurate marker of tumor burden and disease activity in patients with multiple myeloma (MM). This dual-center study aimed at further corroboration of the superiority of MET as positron emission tomography (PET) tracer for staging and re-staging MM, as compared to \(^{18}\)F-2`-deoxy-2`-fluoro-D-glucose (FDG).
78 patients with a history of solitary plasmacytoma (n=4), smoldering MM (SMM, n=5), and symptomatic MM (n=69) underwent both MET- and FDG-PET/computed tomography (CT) at the University Centers of Würzburg, Germany and Navarra, Spain. Scans were compared on a patient and on a lesion basis. Inter-reader agreement was also evaluated. In 2 patients, tumor biopsies for verification of discordant imaging results were available.
MET-PET detected focal lesions (FL) in 59/78 subjects (75.6%), whereas FDG-PET/CT showed lesions in only 47 patients (60.3%; p<0.01), accordingly disease activity would have been missed in 12 patients. Directed biopsies of discordant results confirmed MET-PET/CT results in both cases.
MET depicted more FL in 44 patients (56.4%; p<0.01), whereas in two patients (2/78), FDG proved superior. In the remainder (41.0%, 32/78), both tracers yielded comparable results. Inter-reader agreement for MET was higher than for FDG (κ = 0.82 vs κ = 0.72).
This study demonstrates higher sensitivity of MET in comparison to standard FDG to detect intra- and extramedullary MM including histologic evidence of FDG-negative, viable disease exclusively detectable by MET-PET/CT. MET holds the potential to replace FDG as functional imaging standard for staging and re-staging of MM.